CJ Healthcare Awarded Grand Prize
Mar.4, 2019
CJ Healthcare Awarded Grand Prize of Korea New Drug Development and Minister Award from Ministry of Health and Welfare
- Won the Grand Prize in the Korea New Drug Development Award for his contribution to the success of K-CAB Tab. Development, which is both the New Drug for Gastroesophageal reflux disease and Korea’s 30th new drug
- Research Director Kim, Bong-Tae (CJ Healthcare Clinical Center), Awarded Minister Award from the Ministry of Health and Welfare
CJ Healthcare (CEO Kang Seok-Hee) announced on the 4th that the company won the Grand Prize in the Korea New Drug Development Award for the development achievement of 'K-CAB Tab.(ingredient: Tegoprazan)’, which is Korea’s 30th new drug, at the 20th Korea New Drug Development Award ceremony hosted by Korea New Drug Development Research Association held at Samjung Hotel, Seoul(Kangnam-Ku) on the 28th of Feb.
CJ Healthcare has won the Korea New Drug Development Award for the first time after receiving the technology export prize in 2016 for K-CAB Tab., a new drug for gastroesophageal reflux disease.
K-CAB Tab., meaning ‘A P-CAB of KOREA’, is a new drug of P-CAB(Potassium Competitive Acid Blocker) class, acquires primary indications for both ERD(erosive gastroesophageal reflux disease) and NERD(non-erosive gastroesophageal reflux disease). It was approved as Korea’s 30th new drug in July of last year and it was launched with health insurance coverage on the 1st of this month (March).
K-CAB Tab. is characterized by 'fast drug efficacy', and ‘inhibition of nighttime gastric acid secretion.’ Once a day, when one dose was given, the maximum gastric acid secretion was suppressed from the first day of administration. In addition, the gastric pH in the stomach was maintained at 4 or higher for 24 hours, confirming the effect of inhibiting gastric acid secretion at night and providing excellent safety.
K-CAB Tab. has entered into the Chinese market with a contract to export technology to Luoxin, China in 2015 worth a total of US $ 95.29 million (KRW114.3 billion), and after that last year, it has entered Vietnam market by signing export agreement with Vimedimex Medi Pharma from Vietnam.
Recently, the company has signed a licensing agreement with Carnot in Mexica(Laboratorios Carnot) and 17 other Latin American countries to supply K-CAB Tab. exclusively for a total of about $ 84 million (about KRW100.8 billion). K-CAB Tab. has been expanding its activities as a global new drug by entering 20 countries around the world including China, Vietnam and 17 Central and South American countries as well as Korea.
CJ Healthcare CEO Kang Seok-Hee said, "A P-CAB of KOREA, 'K-CAB' will cross the Republic of Korea and grow into a global gastroesophageal reflux disease drug to promote Korea's new drug R & D capability." in his acceptance speech.
The Korea New Drug Development Award, which is held 20 times this year for all industries, is private-led, government-sponsored and enacted first time in Korea as the most prestigious new drug development award. The award was enacted in April 1999 by the Korea New Drug Development Research Association, sponsored by the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Trade, Industry and Energy to develop domestic biohealth industry and to encourage new drug research and development.
Meanwhile on the same day in the 20th Korea New Drug Development Award, Kim Bong-Tae, director of CJ Healthcare Clinical Center, received the commendation of Minister Award from the Ministry of Health and Welfare for his contribution to the success of K-CAB Tab. Development.
CJ Healthcare research director Kim Bong-Tae said, "K-CAB was able to come out to the world thanks to the fact that I have run from the whole value chain toward the goal of domestic new drug development. We will focus on research on innovative new drugs that can improve the quality of life in the future."
The research director award of The Korea New Drug Development Award was enacted by the approval of the Minister of Health and Welfare Ministry. It is awarded among the researchers belonging to the Korea New Drug Development Awardee, who has contributed to the research and development and has played a key role in achieving attainment by actively discovering and recognizing him/her to promote their morale. Through these efforts, it aims to strengthen the competitiveness of the pharmaceutical industry and to promote research and development of new drugs.